The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 9, 2014, Pages 1969-1977

  Ruvolo, Peter P ^a   Ruvolo, Vivian R ^a   Jacamo, Rodrigo ^a   Burks, Jared K ^a   Zeng, Zhihong ^a   Duvvuri, Seshagiri R ^a   Zhou, Liran ^a   Qiu, Yihua ^a   Coombes, Kevin R ^a   Zhang, Nianxiang ^a   Yoo, Suk Y ^a   Pan, Rongqing ^a   Hail, Numsen ^a   Konopleva, Marina ^a   Calin, George ^a   Kornblau, Steven M ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; B55 ; Cell signaling; MiR 142; MiR 191; Relapse

Indexed keywords

FINGOLIMOD; ISOPROTEIN; MICRORNA; MICRORNA 191; MICRORNA 191 5P; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2A REGULATORY SUBUNIT B55ALPHA; PROTEIN KINASE C ALPHA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOICHIOMETRY;

AML; B55Α; CELL SIGNALING; MIR-142; MIR-191; RELAPSE;

DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROPYLENE GLYCOLS; PROTEIN KINASE C-ALPHA; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOSINE; SRC-FAMILY KINASES;

EID: 84902477545     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.05.006     Document Type: Article

References (37)

1. Andreeff M., Milella M., Carter B.Z., Tabe Y., Ricciardi M.R., Sneed T., et al. Targeted therapy of AML new concepts. Ann. Hematol. 2004, 83(Suppl. 1):S51-S53.
2. Kantarjian H., O'Brien S., Cortes J., Wierda W., Faderl S., Garcia-Manero G., et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40years. Cancer 2008, 113:1933-1952.
3. Scott E., Hexner E., Perl A., Carroll M. Targeted signal transduction therapies in myeloid malignancies. Curr. Oncol. Rep. 2010, 12:358-365.
4. Estey E.H. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am. J. Hematol. 2013, 88:318-327.
5. Ruvolo P.P., Qui Y.H., Coombes K.R., Zhang N., Ruvolo V.R., Borthakur G., et al. Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete RD in acute myeloid leukemia patients. Leukemia 2011, 25:1711-1717.
6. Walter R.B., Kantarjian H.M., Huang X., Pierce S.A., Sun Z., Gundacker H.M., et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J. Clin. Oncol. 2010, 28:1766-1771.
7. Kuo Y.C., Huang K.Y., Yang C.H., Yang Y.S., Lee W.Y., Chiang C.W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 2008, 283:1882-1892.
8. Schmitz M.H., Held M., Janssens V., Hutchins J.R., Hudecz O., Ivanova E., et al. Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells. Nat. Cell Biol. 2010, 12:886-893.
9. Alvarez-Fernández M., Halim V.A., Aprelia M., Laoukili J., Mohammed S., Medema R.H. Protein phosphatase 2A (B55α) prevents premature activation of forkhead transcription factor FoxM1 by antagonizing cyclin A/cyclin-dependent kinase-mediated phosphorylation. J. Biol. Chem. 2011, 286:33029-33036.
10. Garzon R., Volinia S., Liu C.G., Fernandez-Cymering C., Palumbo T., Pichiorri F., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
11. Wang X.S., Gong J.N., Yu J., Wang F., Zhang X.H., Tan Z.Q., et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012, 119:4992-5004.
12. Kwanhian W., Lenze D., Alles J., Motsch N., Barth S., Döll C., et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 2012, 1:141-155.
13. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074.
14. Kornblau S.M., Singh N., Qiu Y., Chen W., Zhang N., Coombes K.R. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin. Cancer Res. 2010, 16:1865-1874.
15. Hu J., He X., Baggerly K.A., Coombes K.R., Hennessy B.T., Mills G.B. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007, 23:1986-1994.
16. Neeley E.S., Kornblau S.M., Coombes K.R., Baggerly K.A. Variable slope normalization of reverse phase protein arrays. Bioinformatics 2009, 25:1384-1389.
17. Kornblau S.M., Tibes R., Qiu Y.H., Chen W., Kantarjian H.M., Andreeff M., et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113:154-164.
18. Janssens V., Longin S., Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem. Sci. 2008, 33:113-121.
19. Strack S., Cribbs J.T., Gomez L. Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J. Biol. Chem. 2004, 279:47732-47739.
20. Boone D.N., Hann S.R. The Myc-ARF-Egr1 pathway: unleashing the apoptotic power of c-Myc. Cell Cycle 2011, 10:2043-2044.
21. Arnold H.K., Sears R.C. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol. Cell. Biol. 2006, 26:2832-2844.
22. Liu L., Eisenman R.N. Regulation of c-Myc protein abundance by a protein phosphatase 2A-glycogen synthase kinase 3β-negative feedback pathway. Genes Cancer 2012, 3:23-36.
23. Yang Y., Huang Q., Lu Y., Li X., Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J. Cell. Biochem. 2012, 113:1314-1322.
24. Ruvolo V.R., Kurinna S.M., Karanjeet K.B., Schuster T.F., Martelli A.M., McCubrey J.A., et al. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J. Biol. Chem. 2008, 283:35474-35485.
25. Aguda B.D., Kim Y., Piper-Hunter M.G., Friedman A., Marsh C.B. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19678-19683.
26. Li L., Abdel Fattah E., Cao G., Ren C., Yang G., Goltsov A.A., et al. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res. 2008, 68:434-443.
27. Perrotti D., Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013, 14:e229-e238.
28. Janssens V., Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr. Mol. Med. 2012, 12:268-287.
29. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
30. Liu W., Xie C.C., Zhu Y., Li T., Sun J., Cheng Y., et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008, 10:897-907.
31. Mosca L., Musto P., Todoerti K., Barbieri M., Agnelli L., Fabris S., et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am. J. Hematol. 2013, 88:16-23.
32. Montero J.C., Seoane S., Ocaña A., Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 2011, 17:5546-5552.
33. Kalev P., Simicek M., Vazquez I., Munck S., Chen L., Soin T., et al. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res. 2012, 72:6414-6424.
34. Reid M.A., Wang W.I., Rosales K.R., Welliver M.X., Pan M., Kong M. The B55α subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol. Cell 2013, 50:200-211.
35. Lorca T., Castro A. The Greatwall kinase: a new pathway in the control of the cell cycle. Oncogene 2013, 32:537-543.
36. Liu X., Sempere L.F., Ouyang H., Memoli V.A., Andrew A.S., Luo Y., et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 2010, 120:1298-1309.
37. Dahlhaus M., Roolf C., Ruck S., Lange S., Freund M., Junghanss C. Expression and prognostic significance of hsa-miR-142-3p in acute leukemias. Neoplasma 2013, 60:432-438.